Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Braxia Scientific’s subsidiary CRTCE clinic Trial establishes psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment TORONTO, Dec. 14, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC…


Previous articlePT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative Financing Vine
Next articleEditor’s Choice Award 2021-Best Study on Psychedelics and Neuroplasticity